Level A· Stronger Clinical EvidenceRandomized Controlled TrialEurope PMC

Stem cell therapy for chronic ischaemic heart disease and congestive heart failure

Fisher SA., Doree C., Mathur A., Taggart DP., Martin-Rendon E.

Randomized Controlled Trial with a reported sample of 1907 on Cardiovascular Disease, Stroke Research, published in Cochrane Database Syst Rev (2016) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Cochrane Database Syst Rev (2016)
Reported sample size
1907
Source database
Europe PMC
PMID
28012165
PMCID
PMC6463978
DOI
10.1002/14651858.cd007888.pub3
Citations
91

Abstract (original English)

Background A promising approach to the treatment of chronic ischaemic heart disease and congestive heart failure is the use of stem cells. The last decade has seen a plethora of randomised controlled trials developed worldwide, which have generated conflicting results. Objectives The critical evaluation of clinical evidence on the safety and efficacy of autologous adult bone marrow-derived stem/progenitor cells as a treatment for chronic ischaemic heart disease and congestive heart failure. Search methods We searched CENTRAL in the Cochrane Library, MEDLINE, Embase, CINAHL, LILACS, and four ongoing trial databases for relevant trials up to 14 December 2015. Selection criteria Eligible studies were randomised controlled trials comparing autologous adult stem/progenitor cells with no cells in people with chronic ischaemic heart disease and congestive heart failure. We included co-interventions, such as primary angioplasty, surgery, or administration of stem cell mobilising agents, when administered to treatment and control arms equally. Data collection and analysis Two review authors independently screened all references for eligibility, assessed trial quality, and extracted data. We undertook a quantitative evaluation of data using random-effects meta-analyses. We evaluated heterogeneity using the I 2 statistic and explored substantial heterogeneity (I 2 greater than 50%) throug

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Bone Marrow CellsHumansMyocardial IschemiaMyocardial InfarctionChronic DiseaseStroke VolumeHospitalizationPatient ReadmissionStem Cell TransplantationAdult Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research